Title:
PHARMACEUTICAL COMPOSITION AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/059962
Kind Code:
A1
Abstract:
Provided is a pharmaceutical composition containing a therapeutically effective amount of furmonertinib or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier, and use of furmonertinib or a pharmaceutically acceptable salt thereof, or said pharmaceutical composition in manufacture of a medicament for treating and/or preventing a disease mediated by PACC mutation. The pharmaceutical composition shows an excellent therapeutic effect of disease mediated by PACC mutation (for example, non-small cell lung cancer (NSCLC)) with little side effects and excellent safety.
Inventors:
LUO HUIBING (CN)
LI QING (CN)
HSU JERRY (US)
MUSIB LUNA (US)
LUTZKER STUART (US)
KOWANETZ MARCIN (US)
LI QING (CN)
HSU JERRY (US)
MUSIB LUNA (US)
LUTZKER STUART (US)
KOWANETZ MARCIN (US)
Application Number:
PCT/CN2022/119568
Publication Date:
March 28, 2024
Filing Date:
September 19, 2022
Export Citation:
Assignee:
SHANGHAI ALLIST PHARMACEUTICALS CO LTD (CN)
International Classes:
A61K31/506; A61P35/00; A61P35/04
Domestic Patent References:
| WO2021239786A1 | 2021-12-02 |
Foreign References:
| CN116159062A | 2023-05-26 | |||
| CN107163026A | 2017-09-15 | |||
| CN105315259A | 2016-02-10 |
Other References:
SHI YUANKAI, HU XINGSHENG, ZHANG SHUCAI, LV DONGQING, WU LIN, YU QITAO, ZHANG YIPING, LIU LI, WANG XIANG, CHENG YING, MA ZHIYONG, : "Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study", THE LANCET. RESPIRATORY MEDICINE, ELSEVIER, OXFORD, vol. 9, no. 8, 26 March 2021 (2021-03-26), Oxford , pages 829 - 839, XP093046312, ISSN: 2213-2600, DOI: 10.1016/S2213-2600(20)30455-0
XU HAIYAN, YANG GUANGJIAN, LIU RUNZE, YANG YANING, LI WEIHUA, LI JUNLING, HAO XUEZHI, XING PUYUAN, WANG YAN: "EGFR uncommon alterations in advanced non-small cell lung cancer and structural insights into sensitivity to diverse tyrosine kinase inhibitors", FRONTIERS IN PHARMACOLOGY, FRONTIERS RESEARCH FOUNDATION, CH, vol. 13, 16 September 2022 (2022-09-16), CH , pages 976731, XP093150030, ISSN: 1663-9812, DOI: 10.3389/fphar.2022.976731
XU HAIYAN, YANG GUANGJIAN, LIU RUNZE, YANG YANING, LI WEIHUA, LI JUNLING, HAO XUEZHI, XING PUYUAN, WANG YAN: "EGFR uncommon alterations in advanced non-small cell lung cancer and structural insights into sensitivity to diverse tyrosine kinase inhibitors", FRONTIERS IN PHARMACOLOGY, FRONTIERS RESEARCH FOUNDATION, CH, vol. 13, 16 September 2022 (2022-09-16), CH , pages 976731, XP093150030, ISSN: 1663-9812, DOI: 10.3389/fphar.2022.976731
Attorney, Agent or Firm:
CHINA PATENT AGENT (H.K.) LTD. (CN)
Download PDF:
Previous Patent: AUTOMATED ACCESSIBILITY ASSESSMENT TOOL
Next Patent: BATTERY CELL, BATTERY, AND ELECTRIC APPARATUS
Next Patent: BATTERY CELL, BATTERY, AND ELECTRIC APPARATUS